CN1104897A - Jinling capsule - Google Patents
Jinling capsule Download PDFInfo
- Publication number
- CN1104897A CN1104897A CN 93116000 CN93116000A CN1104897A CN 1104897 A CN1104897 A CN 1104897A CN 93116000 CN93116000 CN 93116000 CN 93116000 A CN93116000 A CN 93116000A CN 1104897 A CN1104897 A CN 1104897A
- Authority
- CN
- China
- Prior art keywords
- capsule
- jinling
- radix
- grams
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invented capsule is composed of by weight ratio drie young Bungarus multicinctus 50-150, antelope's horn 50-200, earthworm 400-600, whole scorpin 30-90, dragan's blood 30-100, root of membranous milk vetch 30-150, saline cistanche 30-90, root of Chinese trichosanthes 30150 an centipede 10-15. The indications of said medicine are ischemic cerebrovascular disease, sclerosis of coronary artery, angina pectoris due to thrombi embolism and various hyperostosis due to cervical spondylosis.
Description
The present invention relates to a kind of antithrombotic new drug Jinling capsule for the treatment of embolism class diseases.
At present, it is higher four times than the number that cancer seizes to die from the number of the embolism class diseases that causes because of thrombosis in the world.In recent years at home, the mortality rate of blood embolization diseases such as cardiovascular and cerebrovascular vessel also sharply rises, and become first cause of the death, having become one of current clinical medicine both at home and abroad most important to the formation of the mechanism of thrombosis research and control thereof also is the heat subject that need study.
The antithrombotic reagent of clinical practice both at home and abroad is in general to having certain curative effect the early stage of thrombotic disease, but not remarkable to the therapeutical effect in later stage, and is still unsatisfactory as the curative effect to cerebral infarction sequela.The Hebei traditional Chinese medical science 1988,10(1) .-5 has reported with Agkistrodon, Scolopendra, Hirudo, Rhizoma Chuanxiong, Semen Strychni grinds makes the capsule for treating apoplectic hemiplegia.Chinese medicine journal 1992.7(1) 31~32 reported that ejector half No. 1 ball in ground (contains Cornu Saigae Tataricae, Cornu rhinocerotis, Calculus Bovis, Rhizoma Gastrodiae in the liver-wind with keeping normal life activities health and happiness pill for curing apoplexy sequela, Ramulus Uncariae Cum Uncis, Scorpio, Zaocys, Agkistrodon, Radix Salviae Miltiorrhizae, the Radix Rehmanniae, the Radix Paeoniae Alba, Arisaema Cum Bile, Radix Achyranthis Bidentatae etc.); Qi deficiency blood stasis type (contains the Radix Astragali, Radix Ginseng, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Ramulus Cinnamomi with No. 2 balls, Ramulus Uncariae Cum Uncis, Cornu Saigae Tataricae, Agkistrodon halys, Zaocys, Agkistrodon, Radix Paeoniae Rubra, Radix Achyranthis Bidentatae, Hirudo, Arisaema Cum Bile etc.), qi stagnation and blood stasis type (contains Cornu Saigae Tataricae with No. 3 balls, Rhizoma Gastrodiae, Ramulus Uncariae Cum Uncis, Scorpio, Zaocys, Hirudo, Agkistrodon, Radix Cyathulae, Fructus Aurantii, Olibanum, Myrrha, Squama Manis, Agkistrodon halys, Radix Salviae Miltiorrhizae, Arisaema Cum Bile etc.).More than two medicines treatments apoplectic hemiplegia certain shortcomings and deficiencies are all arranged.The former often changes by taking dose, and the patient is difficult for grasping, and toxic reaction easily takes place; The latter is multiple prescription then, is close ball, and the patient is difficult for selecting, and is difficult for taking.
The objective of the invention is: develop a kind of treatment ischemic cerebrovascular, promptly by coronary atherosclerosis in the atherosis cerebral thrombosis that causes of cerebrovascular inwall and cerebral embolism and the heart disease, the angina pectoris that thromboembolism causes, myocardial infarction, all kinds of hyperosteogenys that cause by cervical spondylosis, moving obstacle, spinal canal stenosis, the antithrombotic new drug of disease such as intercalated disc is outstanding.
The present invention can realize in the following way.
With containing Cornu Saigae Tataricae, Scolopendra, Pheretima, Scorpio, Bungarus Parvus, the Radix Astragali, Sanguis Draxonis, Herba Cistanches, Radix Trichosanthis are raw material, are by weight: 50~150: 50~200: 400~600: 30~90: 10~15: 30~100: 30~150: 30~90: 30~150 ratio Cheng Fang.Sanguis Draxonis blood stasis dispelling embolism extinguishing, but Herba Cistanches reinforcing kidney and strengthening resistance.Full presciption medicine is played the kidney invigorating altogether, the blood circulation promoting and blood stasis dispelling suppressing the hyperactive liver and subsiding YANG, and the effect of the path that relieves dizziness, high fever, infantile convulsions, epilepsy, etc., Cornu Saigae Tataricae, Scolopendra, Pheretima, Scorpio, Agkistrodon, the Radix Astragali plays the effect of liver heat removing calming wind and dredging collateral.
We also can add weight ratio: 6~18: 6~18: 6~12: 1 Flos Carthami, Rhizoma Gastrodiae, Radix Angelicae Sinensis, Radix Glycyrrhizae.
According to the traditional Chinese medical science rule of treatment and herbal nature theory, this prescription has suppressing the hyperactive liver and subsiding YANG, relieves dizziness, high fever, infantile convulsions, epilepsy, etc. and has one's ideas straightened out, dredge the meridian passage, the effect of blood circulation promoting and blood stasis dispelling.Zooperal result shows that this medicine is to ischemic cerebrovascular, promptly by atherosis cerebral thrombosis that causes of cerebrovascular inwall and cerebral embolism; The angina pectoris that coronary atherosclerosis in the heart disease, thromboembolism cause, diseases such as myocardial infarction have preventive and therapeutic effect.Through 200 routine clinical observations, in the recent period effective percentage is more than 90%, convalescent period effective percentage be more than 60%, period in a medicine is all found the effect of paying, and existing experimental data and clinical setting is reported as follows:
One, experimental technique and data
(1) treated in vitro: contrast adds respectively in the rabbit arterial blood with normal saline and Jinling capsule decoction liquor, test with the platelet adhesion double-purpose instrument with external thrombus formation, with 37 ℃ of constant temperature, revolution 17r/min, rotate after 15 minutes, length and the weight of measuring thrombosis respectively the results are shown in Table 1.
Group | Thrombosis length (cm) | Thrombosis dry weight (mg) | Weight in wet base suppression ratio % | Compare with matched group |
The normal saline group | 4.83±0.46 | 221.25±25.71 | 77.25±8.35 | |
The Jinling capsule group | 1.95±0.22 | 136.88±0.16 | 33.13±4.58 | 38.1P〈0.05 |
(2) vivo medicine-feeding: divide three groups with rabbit, give normal saline respectively, Jinling capsule and NIAOXUEKANG KOUFUYE, once a day, continuous 7 days, the method for using was measured thrombosis length and weight, the results are shown in Table 2
Group | Thrombosis length (cm) | Thrombosis humidity (mg) | Weight in wet base suppression ratio % | Compare with matched group |
The normal saline group | 5.13±0.50 | 205±6.55 | 116.1±8.10 | |
The Jinling capsule group | 2.56±0.43 | 84±3.80 | 27.3±14.7 | 59.0P〈0.01 |
NIAOXUEKANG KOUFUYE | 2.64±0.79 | 84.4±5.85 | 32.3±1.29 | 58.8P〈0.01 |
The result shows, no matter experiment in vitro or vivo medicine-feeding, and Jinling capsule all has the obvious suppression effect to inside and outside thrombosis.
2, to the influence of platelet adhesion
Divide three groups with rabbit, respectively with normal saline, Jinling capsule decoction liquor NIAOXUEKANG KOUFUYE is irritated stomach, once a day, gets blood test respectively, result such as table 3 after 7 days.
The influence of table 3 pair platelet adhesion
Group | Adhesion rate % | Compare with matched group |
Normal saline | 17.44±0.15 | |
Jinling capsule | 11.41±0.43 | P〈0.01 |
NIAOXUEKANG KOUFUYE | 13.19±0.16 | P〈0.01 |
The result shows that Jinling capsule has obvious inhibitory action to platelet adhesion.
3, to the influence of clotting time
Divide three groups with rabbit, give normal saline Jinling capsule decoction liquor and NIAOXUEKANG KOUFUYE respectively and irritate stomach, once a day, successive administration 7 days, extracting arterial blood are pressed the sheet glass method and are measured clotting time, the results are shown in Table 4
The influence of table 4 pair clotting time
Group | Adhesion rate % | Compare with matched group |
Normal saline | 3.17±0.02 | |
Jinling capsule | 4.17±0.04 | P〈0.01 |
NIAOXUEKANG KOUFUYE | 4.43±0.10 | P〈0.01 |
The result shows that Jinling capsule can prolong clotting time significantly.
4, toxicity test
Acute toxicity test in mice: once irritate stomach 10g/kg Jinling capsule for mice, do not see dead mouse in 7 days, have no adverse reaction, the result shows that Jinling capsule gastric infusion toxicity is low.
Above zoopery result shows that Jinling capsule can suppress the formation and the platelet adhesion rate of thrombosis, obviously prolongs clotting time, is the effective pharmacological basis of its control thrombotic disease.
This medicine is in the clinical research of control cerebral thrombosis disease
Selection meets 45 parts of cerebral thrombosis that diagnosis requires and sequela cases thereof, male 29 people wherein, and women 16 people, the age, the course of disease had acute attack in time to be in hospital between 40~81, and the ill recurrence more than 2 years is also arranged.Except that the emergency case disease, other patient all uses this medicine separately after being in hospital.Therapeutic Method is: oral three times of every day, each 2, Time of Administration is as short as 30 days, 60 days at most.
According to the diagnostic criteria of the unified regulation of national traditional Chinese medical science meeting, therapeutic outcome is divided into is almost recovered, produce effects, effectively, invalid four classes:
Statistical result is as follows:
Be almost recovered: 14 31.1% produce effects: 21 46.6%
Effectively: 8 17.7% is invalid: 2 4.4%
Total effective rate is: 95.6%
This medicine is in the clinical research of treatment prolapse of lumbar intervertebral disc
Man's 19 examples, women 11 examples, totally 30 examples, the oldest 60 years old, minimum 21 years old, 42.2 years old mean age.Medical history is the longest 3 years, one week of weak point person.X-ray examination, lumbar vertebra physiological bending change 19 examples (lateral bending 12 examples wherein, gap turn narrow 15 examples, no significant change 9 examples, Therapeutic Method is: each 1~2, every day 3 times, ten days is a course of treatment, generally takes medicine three courses of treatment.
Statistical result is as follows:
Produce effects: 6 examples are good: 13 examples
Effectively: 9 examples are invalid: 2 examples
Total effective rate is 93.3%
Embodiment:
1. cure mainly cerebral thrombosis and sequela, make 4000 capsules
Bungarus Parvus 90 grams, Cornu Saigae Tataricae 80 grams, Pheretima 520 grams, Scorpio 60 grams, Sanguis Draxonis 50 grams, Scolopendra 50 grams, the Radix Astragali 50 grams, Herba Cistanches 50 grams, Radix Trichosanthis 50 grams.
2. cure mainly prolapse of lumbar intervertebral disc: make 4000 capsules
Bungarus Parvus 90 grams, Cornu Saigae Tataricae 80 grams, Pheretima 520 grams, Scorpio 60 grams, Sanguis Draxonis 50 grams, Scolopendra 50 grams, the Radix Astragali 50 grams, Herba Cistanches 50 grams, Flos Carthami 50 grams, Rhizoma Gastrodiae 60 grams, Radix Angelicae Sinensis 50 grams, Radix Glycyrrhizae 5 grams.
Claims (2)
1, a kind of Jinling capsule, it is characterized in that: by Bungarus Parvus, Cornu Saigae Tataricae, Pheretima, Scorpio, Scolopendra, Sanguis Draxonis, the Radix Astragali, Herba Cistanches, Radix Trichosanthis are by weight: 50~150: 50~200: 400~600: 30~90: 10~15: 30~100: 30~150: 30~90: 30~150 ratio is formed.
2, Jinling capsule according to claim 1 is characterized in that: containing weight ratio is: 6~18: 6~18: 6~12: 1 Flos Carthami, Rhizoma Gastrodiae, Radix Angelicae Sinensis, Radix Glycyrrhizae.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 93116000 CN1104897A (en) | 1993-12-28 | 1993-12-28 | Jinling capsule |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 93116000 CN1104897A (en) | 1993-12-28 | 1993-12-28 | Jinling capsule |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1104897A true CN1104897A (en) | 1995-07-12 |
Family
ID=4991526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 93116000 Pending CN1104897A (en) | 1993-12-28 | 1993-12-28 | Jinling capsule |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1104897A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999026640A1 (en) * | 1997-11-20 | 1999-06-03 | Bukwang Pharm. Ind. Co., Ltd. | Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes |
CN1054770C (en) * | 1996-02-08 | 2000-07-26 | 徐秀琴 | Chinese patent medicine special for treating protrusion of intervertebral disc |
CN1059338C (en) * | 1996-04-23 | 2000-12-13 | 张晓平 | Decoction for curing cerebral vasscular diseases and its producing method |
CN1067891C (en) * | 1997-05-08 | 2001-07-04 | 曾力群 | Pure Chinese drug for curing cerebral thrambus |
CN105816698A (en) * | 2016-06-08 | 2016-08-03 | 江苏天晟药业股份有限公司 | Traditional Chinese medicine composition preventing stroke, preparation method, traditional Chinese medicine preparation and application |
CN108904713A (en) * | 2018-10-08 | 2018-11-30 | 云南中医学院 | A kind of Chinese medicine for treating cardiovascular disease |
-
1993
- 1993-12-28 CN CN 93116000 patent/CN1104897A/en active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1054770C (en) * | 1996-02-08 | 2000-07-26 | 徐秀琴 | Chinese patent medicine special for treating protrusion of intervertebral disc |
CN1059338C (en) * | 1996-04-23 | 2000-12-13 | 张晓平 | Decoction for curing cerebral vasscular diseases and its producing method |
CN1067891C (en) * | 1997-05-08 | 2001-07-04 | 曾力群 | Pure Chinese drug for curing cerebral thrambus |
WO1999026640A1 (en) * | 1997-11-20 | 1999-06-03 | Bukwang Pharm. Ind. Co., Ltd. | Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes |
CN105816698A (en) * | 2016-06-08 | 2016-08-03 | 江苏天晟药业股份有限公司 | Traditional Chinese medicine composition preventing stroke, preparation method, traditional Chinese medicine preparation and application |
CN105816698B (en) * | 2016-06-08 | 2020-01-17 | 江苏天晟药业股份有限公司 | Traditional Chinese medicine composition for preventing and treating stroke, preparation method, traditional Chinese medicine preparation and application |
CN108904713A (en) * | 2018-10-08 | 2018-11-30 | 云南中医学院 | A kind of Chinese medicine for treating cardiovascular disease |
CN108904713B (en) * | 2018-10-08 | 2021-07-16 | 云南中医学院 | Chinese medicine for treating cardiovascular disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1240416C (en) | Medicine for curing hypertension and its preparation method | |
CN111743934A (en) | Traditional Chinese medicine composition for regulating intestinal flora and application thereof | |
CN1232266C (en) | Chinese medicinal capsules for apoplexy and thoracic palsy and preparation thereof | |
CN1104897A (en) | Jinling capsule | |
CN1046421C (en) | Drug for curing pulmonary tuberculosis | |
CN1389255A (en) | Composite Chinese medicine for treating rheumarthritis and rheumatoid arthritis | |
CN101041006A (en) | Composite Chinese medicine took orally for treating coronary heart disease | |
CN1135909A (en) | Medicine for hyperosteogeny and wind-cold syndrome | |
CN115177669A (en) | Traditional Chinese medicine composition with effect of treating myocardial bridge and application thereof | |
CN1114893A (en) | "Yuanshen" pill-medicine for treatment of encephalatrophy | |
CN1081888A (en) | Treatment commonly encountered diseases of internal department, the apoplexy of frequently-occurring disease and the Chinese patent medicine tablet of sequela | |
CN1312085A (en) | Dermatosis treating medicine | |
WO2022016827A1 (en) | Compound preparation for neuranagenesis, and preparation method therefor and use thereof | |
CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
CN106974958B (en) | Recipe of 'RongjinNiantong' and its prepn and use | |
CN1261123C (en) | Chinese medicine preparation pus drawing out plaster for treating pasteur cystic, furuncle, furunculosis and carbuncle | |
CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
CN108403983A (en) | Treat the stagnation resolvation Cyclandelate of cerebral infarction sequela | |
CN1111038C (en) | Chinese patent medicine for curing thrombotic disease | |
CN1281236C (en) | Chinese medicinal decoction for treating embolus disease | |
CN1181835C (en) | Chinese medicine preparation for treating rheumatism and rheumatoid disease | |
CN1054769C (en) | Chinese medicinal preparation for treatment of psoriasis and preparation method thereof | |
CN1158095C (en) | Chinese medicine for treating rheumatoid arthritis | |
CN1036503C (en) | Medicine for treating systemic lupus erythematosus and producing method thereof | |
CN1308952A (en) | Chinese medicine for treating trigeminal neuraligia and its preparing process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |